Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

44 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Patient-reported outcomes following treatment with the human GLP-1 analogue liraglutide or glimepiride in monotherapy: results from a randomized controlled trial in patients with type 2 diabetes.
Bode BW, Testa MA, Magwire M, Hale PM, Hammer M, Blonde L, Garber A; LEAD-3 Study Group. Bode BW, et al. Among authors: magwire m. Diabetes Obes Metab. 2010 Jul;12(7):604-12. doi: 10.1111/j.1463-1326.2010.01196.x. Diabetes Obes Metab. 2010. PMID: 20590735 Free PMC article. Clinical Trial.
2018 ACC Expert Consensus Decision Pathway on Novel Therapies for Cardiovascular Risk Reduction in Patients With Type 2 Diabetes and Atherosclerotic Cardiovascular Disease: A Report of the American College of Cardiology Task Force on Expert Consensus Decision Pathways.
Das SR, Everett BM, Birtcher KK, Brown JM, Cefalu WT, Januzzi JL Jr, Kalyani RR, Kosiborod M, Magwire ML, Morris PB, Sperling LS. Das SR, et al. Among authors: magwire ml. J Am Coll Cardiol. 2018 Dec 18;72(24):3200-3223. doi: 10.1016/j.jacc.2018.09.020. Epub 2018 Nov 26. J Am Coll Cardiol. 2018. PMID: 30497881 Free PMC article. No abstract available.
Use of Lipid-, Blood Pressure-, and Glucose-Lowering Pharmacotherapy in Patients With Type 2 Diabetes and Atherosclerotic Cardiovascular Disease.
Nelson AJ, O'Brien EC, Kaltenbach LA, Green JB, Lopes RD, Morse CG, Al-Khalidi HR, Aroda VR, Cavender MA, Gaynor T, Kirk JK, Lingvay I, Magwire ML, McGuire DK, Pak J, Pop-Busui R, Richardson CR, Senyucel C, Kelsey MD, Pagidipati NJ, Granger CB. Nelson AJ, et al. Among authors: magwire ml. JAMA Netw Open. 2022 Feb 1;5(2):e2148030. doi: 10.1001/jamanetworkopen.2021.48030. JAMA Netw Open. 2022. PMID: 35175345 Free PMC article.
Incorporating SGLT2i and GLP-1RA for Cardiovascular and Kidney Disease Risk Reduction: Call for Action to the Cardiology Community.
Nelson AJ, Pagidipati NJ, Aroda VR, Cavender MA, Green JB, Lopes RD, Al-Khalidi H, Gaynor T, Kaltenbach LA, Kirk JK, Lingvay I, Magwire ML, O'Brien EC, Pak J, Pop-Busui R, Richardson CR, Reed M, Senyucel C, Webb L, McGuire DK, Granger CB. Nelson AJ, et al. Among authors: magwire ml. Circulation. 2021 Jul 6;144(1):74-84. doi: 10.1161/CIRCULATIONAHA.121.053766. Epub 2021 Jul 6. Circulation. 2021. PMID: 34228476 Review.
Cardiometabolic Center of Excellence: A Novel Care Delivery Model for Secondary Prevention of Cardiovascular Disease in Type 2 Diabetes.
Thomas M, Magwire M, Gosch K, Sammour Y, Mehta R, O'Keefe J, Nassif ME, Kosiborod M. Thomas M, et al. Among authors: magwire m. Circ Cardiovasc Qual Outcomes. 2021 Oct;14(10):e007682. doi: 10.1161/CIRCOUTCOMES.120.007682. Epub 2021 Sep 30. Circ Cardiovasc Qual Outcomes. 2021. PMID: 34587753 Free PMC article. No abstract available.
Effects of GLP-1 receptor agonists and SGLT-2 inhibitors in heart transplant patients with type 2 diabetes: Initial report from a cardiometabolic center of excellence.
Sammour Y, Nassif M, Magwire M, Thomas M, Fendler T, Khumri T, Sperry BW, O'Keefe J, Kosiborod M. Sammour Y, et al. Among authors: magwire m. J Heart Lung Transplant. 2021 Jun;40(6):426-429. doi: 10.1016/j.healun.2021.02.012. Epub 2021 Feb 22. J Heart Lung Transplant. 2021. PMID: 33745782
44 results